Filter

771-780 of 810 results

  • Questions about Prescription Drug Importation? KFF Has Answers

    News Release

    With lowering prescription drug costs a top priority for Americans, the Trump Administration, presidential candidates, members of Congress, and several states are proposing to allow the importation of drugs from abroad, chiefly Canada. The idea of allowing drugs to be imported from Canada and other countries is popular with Americans across the political spectrum, but has yet to be implemented due to concerns about safety, and strong opposition from the drug industry. A new KFF…

  • Medicaid Coverage of and Spending on GLP-1s

    Issue Brief

    This brief discusses the current landscape of Medicaid GLP-1 coverage and examines recent trends in Medicaid prescriptions and gross spending on GLP-1s.

  • Skepticism Surrounding ADHD Diagnoses and Medication — The Monitor

    Feature

    This volume examines the impact of recent executive actions on federal health communication, along with concerns and stigmas surrounding ADHD diagnoses and treatments, including skepticism about pharmaceutical influence on medication promotion. It also explores distrust in food regulations following the FDA’s ban on Red Dye No. 3.

  • KFF Prescription Drug Advertisements Poll: January 2025

    Poll Finding

    KFF’s January 2025 Prescription Drug Advertisements Poll looks at the public's experiences with prescription drug advertisements, whether they've talked to a doctor about advertised drugs, and how this has influenced the care they receive.

  • How Many People with Employer-Sponsored Insurance Use the Drugs Slated for Medicare Price Negotiations

    Issue Brief

    Among the 167 million people with employer-sponsored insurance in 2022, 3.4 million used at least one of the first 10 drugs identified for Medicare price negotiations, according to a new analysis. The most used drug for people with employer-sponsored health insurance was Jardiance, a drug used to treat diabetes and heart failure, which was taken by more than 911,000 enrollees. The analysis uses the Merative MarketScan 2022 commercial claims to estimate the number of enrollees…

  • Insurer Strategies to Control Costs Associated with Weight Loss Drugs

    Issue Brief

    Affordable Care Act (ACA) Marketplace plans rarely cover GLP-1 drugs approved solely for obesity treatment, according to a an analysis of 2024 federal plan data. Wegovy, a drug that is approved for weight loss, is covered by just 1% of Marketplace prescription drug plans, compared to 82% of Marketplace prescription drug plans for Ozempic, which contains the same active ingredient as Wegovy (semaglutide) but is approved only for diabetes. This analysis examines publicly available formularies…